[1]
|
Wang J, Zuo CT, Jiang YP, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages[J]. J Neurol, 2007, 254(2):185-190. DOI:10.1007/s00415-006-0322-9. |
[2]
|
Ma Y, Dhawan V, Mentis M, et al. Parametric mapping of[18F]FPCIT binding in early stage Parkinson's disease:a PET study[J]. Synapse, 2002, 45(2):125-133. DOI:10.1002/syn.10090. |
[3]
|
许靖, 李肖红, 秦永德, 等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志, 2016, 40(5):338-344. DOI:10.3760/cma.j.issn.1673-4114. 2016.05.003.
Xu J, Li XH, Qin YD, et al. Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson's disease[J]. Int J Radiat Med Nucl Med, 2016, 40(5):338-344. doi: 10.3760/cma.j.issn.1673-4114.2016.05.003 |
[4]
|
Jankovic J. Parkinson's disease:clinical features and diagnosis[J]. J Neurol Neurosurg Psychiatry, 2008, 79(4):368-376. DOI:10.1136/jnnp.2007.131045. |
[5]
|
Morón JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter:evidence from knock-out mouse lines[J]. J Neurosci, 2002, 22(2):389-395. |
[6]
|
Thobois S, Jahanshahi M, Pinto S, et al. PET and SPECT functional imaging studies in Parkinsonian syndromes:from the lesion to its consequences[J]. Neuroimage, 2004, 23(1):1-16. DOI:10.1016/j.neuroimage.2004.04.039. |
[7]
|
李英华, 关锋, 代玉银, 等.正电子放射性分子显像剂诊断帕金森氏病的研究进展[J].核技术, 2012, 35(3):211-215.
Li YH, Guan F, Dai YY, et al. Positron radioactive molecular imaging agents for early diagnosis of Parkinson's disease[J]. Nucl Tech, 2012, 35(3):211-215. |
[8]
|
Huang T, Wang H, Tang G, et al. The influence of residual nor-β-CFT in 11C CFT injection on the Parkinson disease diagnosis:a 11C CFT PET study[J]. Clin Nucl Med, 2012, 37(8):743-747. DOI:10.1097/RLU.0b013e31824c5fae. |
[9]
|
Hung JC. Bringing new PET drugs to clinical practice-a regulatory perspective[J]. Theranostics, 2013, 3(11):885-893. DOI:10.7150/thno.5513. |
[10]
|
Zhu L, Ploessl K, Kung HF. Chemistry. expanding the scope of fluorine tags for PET imaging[J]. Science, 2013, 342(6157):429-430. DOI:10.1126/science.1245011. |
[11]
|
乔晋萍, 乔洪文, 武仙英, 等.多巴胺神经系统显像分子探针研究[J].生命的化学, 2014, 34(2):154-165. DOI:10.13488/j.smhx.20140204.
Qiao JP, Qiao HW, Wu XY, et al. Recent advances in PET tracers for imaging of the dopaminergic system[J]. Chem Life, 2014, 34(2):154-165. doi: 10.13488/j.smhx.20140204 |
[12]
|
甘红梅, 乔晋萍, 孔爱英, 等.正电子放射性显像剂代谢及其研究方法进展[J].国际放射医学核医学杂志, 2010, 34(2):65-71. DOI:10.3760/cma.j.issn.1673-4114.2010.02.001.
Gan HM, Qiao JP, Kong AY, et al. The progress on researching method and metabolism of positron radiopharmaceutical[J]. Int J Radiat Med Nucl Med, 2010, 34(2):65-71. doi: 10.3760/cma.j.issn.1673-4114.2010.02.001 |
[13]
|
Quincoces G, Peñuelas I, Valero M, et al. Simple automated system for simultaneous production of 11C-labeled tracers by solid supported methylation[J]. Appl Radiat Isot, 2006, 64(7):808-811. DOI:10.1016/j.apradiso.2006.03.001. |
[14]
|
Elmaleh DR, Fischman AJ, Shoup TM, et al. Preparation and biological evaluation of iodine-125-IACFT:a selective SPECT agent for imaging dopamine transporter sites[J]. J Nucl Med, 1996, 37(7):1197-1202. |
[15]
|
Fischman AJ, Bonab AA, Babich JW, et al.[11C, 127I] Altropane:a highly selective ligand for PET imaging of dopamine transporter sites[J]. Synapse, 2001, 39(4):332-342. DOI:10.1002/1098-2396(20010315)39:4<332::AID-SYN1017>3.0.CO;2-X. |
[16]
|
Dutta AK, Zhang S, Kolhatkar R, et al. Dopamine transporter as target for drug development of cocaine dependence medications[J]. Eur J Pharmacol, 2003, 479(1/3):93-106. DOI:10.1016/j.ejphar.2003.08.060. |
[17]
|
张锦明, 田嘉禾, 郭喆, 等.在线自动化制备多巴胺转运蛋白显像剂11C-β-CFT[J].中华核医学杂志, 2005, 25(3):142-145. DOI:10.3760/cma.j.issn.2095-2848.2005.03.006.
Zhang JM, Tian JH, Guo Z, et al. Automated on-line preparation of 11C-β-CFT, a dopamine transporter imaging agent[J]. Chin J Nucl Med, 2005, 25(3):142-145. doi: 10.3760/cma.j.issn.2095-2848.2005.03.006 |
[18]
|
Rinne JO, Bergman J, Ruottinen H, et al. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease[J]. Synapse, 1999, 31(2):119-124. DOI:10.1002/(SICI) 1098-2396(199902)31:2<119::AID-SYN4>3.0.CO;2-O. |
[19]
|
Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo[123I] β-CIT binding to dopamine transporters in healthy human subjects[J]. J Cereb Blood Flow Metab, 1994, 14(6):982-994. DOI:10.1038/jcbfm.1994.131. |
[20]
|
Djaldetti R, Treves TA, Ziv I, et al. Use of a single[123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease[J]. Neurol Sci, 2009, 30(4):301-305. DOI:10.1007/s10072-009-0100-4. |
[21]
|
Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT[J]. J Nucl Med, 1996, 37(7):1129-1133. |
[22]
|
Madras BK, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:Ⅰ. Dopamine transporter binding in primate brain[J]. Synapse, 1998, 29(2):93-104. DOI:10.1002/(SICI)1098-2396(199806)29:2<93::AID-SYN1>3.0.CO;2-5. |
[23]
|
Madras BK, Gracz LM, Meltzer PC, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: Ⅱ. Distritution to dopamine-rich region of primate brain[J]. Synapse, 1998, 29(2):105-115. DOI:10.1002/(SICI)1098-2396(199806)29:2<105:AID-SYN2>3.0.CO;2-B. |
[24]
|
Madras BK, Gracz LM, Fahey MA, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:Ⅲ. Human dopamine transporter in postmortem normal and Parkinson's diseased brain[J]. Synapse, 1998, 29(2):116-127. DOI:10.1002/(SICI)1098-2396(199806)29:2<116:AID-SYN3>3.0.CO;2-A. |
[25]
|
Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane:a selective ligand for dopamine transporters[J]. Synapse, 1998, 29(2):128-141. DOI:10.1002/(SICI)1098-2396(199806)29:2<128:AID-SYN4>3.0.CO;2-9. |
[26]
|
Spencer TJ, Madras BK, Bonab AA, et al. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using[11C] altropane and[11C] raclopride[J]. Biol Psychiatry, 2010, 68(10):964-970. DOI:10.1016/j.biopsych.2010.08.026. |
[27]
|
Spencer TJ, Biederman J, Faraone SV, et al. Functional genomics of attention-deficit/hyperactivity disorder(ADHD) risk alleles on dopamine transporter binding in ADHD and healthy control subjects[J]. Biol Psychiatry, 2013, 74(2):84-89. DOI:10.1016/j.biopsych.2012.11.010. |
[28]
|
Marquie M, Locascio JJ, Rentz DM, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study[J/OL]. Alzheimers Res Ther, 2014, 6(5-8): 52[2017-10-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245149. DOI: 10.1186/s13195-014-0052-7. |
[29]
|
Rieckmann A, Gomperts SN, Johnson KA, et al. Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases[J/OL]. Neuroimage Clin, 2015, 8: 554-559[2017-10-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484547. DOI: 10.1016/j.nicl.2015.06.001. |
[30]
|
Rieckmann A, Hedden T, Younger AP, et al. Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity[J]. Hum Brain Mapp, 2016, 37(2):621-631. DOI:10.1002/hbm.23054. |
[31]
|
Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system[J]. Curr Med Chem, 2006, 13(18):2139-2153. DOI:10.2174/092986706777935258. |
[32]
|
李海峰, 张晓军, 张锦明, 等.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志, 2016, 40(3):218-224. DOI:10.3760/cma.j.issn.1673-4114. 2016.03.011.
Li HF, Zhang XJ, Zhang JM, et al. Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J]. Int J Radiat Med Nucl Med, 2016, 40(3):218-224. doi: 10.3760/cma.j.issn.1673-4114.2016.03.011 |